Table 1 Patient characteristics at baseline
|  | Omeprazole group (n = 139) | Famotidine group (n = 129) | Mosapride group (n = 118) | Teprenone group (n = 68) | ||||
|---|---|---|---|---|---|---|---|---|
Men, n (%) | 60 | (43.2%) | 48 | (37.2%) | 40 | (33.9%) | 29 | (42.6%) |
Age y, n (%) | ||||||||
 ≤39 | 72 | (51.8%) | 70 | (54.3%) | 61 | (51.7%) | 41 | (60.3%) |
 40–59 | 52 | (37.4%) | 51 | (39.5%) | 45 | (38.1%) | 21 | (30.9%) |
 ≥60 | 15 | (10.8%) | 8 | (6.2%) | 12 | (10.2%) | 6 | (8.8%) |
Age, y (mean ± SD) | 40.9 ± 13.6 | 39.4 ± 12.6 | 40.0 ± 13.2 | 40.0 ± 12.9 | ||||
BMI, kg/m 2 | ||||||||
 <20 | 36 | (25.9%) | 42 | (32.6%) | 33 | (28.0%) | 20 | (29.4%) |
 20–24 | 79 | (56.8%) | 65 | (50.4%) | 64 | (54.2%) | 39 | (57.4%) |
 ≥25 | 24 | (17.3%) | 22 | (17.1%) | 21 | (17.8%) | 9 | (13.2%) |
BMI, kg/m 2 (mean ± SD) | 22.3 ± 3.5 | 21.9 ± 3.0 | 22.0 ± 3.2 | 21.7 ± 3.0 | ||||
Smoking status (cigarettes/day) | ||||||||
 None | 101 | (72.7%) | 101 | (78.3%) | 93 | (78.8%) | 47 | (69.1%) |
 <20 | 35 | (25.2%) | 20 | (15.5%) | 19 | (16.1%) | 16 | (23.5%) |
 ≥20 | 3 | (2.2%) | 8 | (6.2%) | 6 | (5.1%) | 5 | (7.4%) |
Alcohol intake | ||||||||
 None | 59 | (42.4%) | 55 | (42.6%) | 42 | (35.6%) | 22 | (32.4%) |
 Occasionally | 58 | (41.7%) | 53 | (41.1%) | 45 | (38.1%) | 32 | (47.1%) |
 Every day | 22 | (15.8%) | 21 | (16.3%) | 31 | (26.3%) | 14 | (20.6%) |
Concurrent disease | ||||||||
 Absent | 111 | (79.9%) | 114 | (88.4%) | 98 | (83.1%) | 62 | (91.2%) |
 Present | 28 | (20.1%) | 15 | (11.6%) | 20 | (16.9%) | 6 | (8.8%) |